This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, A.
Right arrow Articles by Bilezikian, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, A.
Right arrow Articles by Bilezikian, J.
Related Collections
Right arrow Other endocrinology
Right arrow Osteoporosis
Right arrow Menopause (including HRT)
CMAJ • July 25, 2000; 163 (2)
© 2000 Canadian Medical Association or its licensors

Review
Synthèse

Primary hyperparathyroidism: pathophysiology and impact on bone

Aliya Khan and John Bilezikian

Dr. Khan is Associate Clinical Professor of Medicine, McMaster University, Hamilton, Ont., and Dr. Bilezikian is Professor of Medicine, Columbia University College of Physicians and Surgeons, New York, NY.

Abstract

Primary hyperparathyroidism has been associated with bone loss, especially at cortical skeletal sites. Results from studies evaluating the mineral density of cancellous bone have been more difficult to interpret. Most densitometry studies support the concept that the parathyroid hormone appears to be catabolic at cortical sites and may have anabolic effects at cancellous bone sites. Studies completed to date, however, have been limited by design, definitions of fracture and inadequate control groups. Primary hyperparathyroidism is now increasingly being detected during the asymptomatic phase. The need for parathyroidectomy has been questioned in such patients because there may be no disease progression in the absence of surgery. Medical management of primary hyperparathyroidism has to date been limited to estrogen replacement therapy in postmenopausal women. Identification of the calcium receptor has improved our understanding of calcium homeostasis, and significant reductions in calcium receptor levels have been detected in parathyroid adenomas. Thus, a new class of therapeutics may include the calcimimetic agents. Bisphosphonates are also currently being evaluated with regard to their impact on fracture prevention and their beneficial effects on bone mineral density.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
M. Ohishi, R. Chiusaroli, M. Ominsky, F. Asuncion, C. Thomas, R. Khatri, P. Kostenuik, and E. Schipani
Osteoprotegerin Abrogated Cortical Porosity and Bone Marrow Fibrosis in a Mouse Model of Constitutive Activation of the PTH/PTHrP Receptor
Am. J. Pathol., June 1, 2009; 174(6): 2160 - 2171.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. B. Lowry, S. Lotinun, A. A. Leontovich, M. Zhang, A. Maran, K. L. Shogren, B. K. Palama, K. Marley, U. T. Iwaniec, and R. T. Turner
Osteitis Fibrosa Is Mediated by Platelet-Derived Growth Factor-A Via a Phosphoinositide 3-Kinase-Dependent Signaling Pathway in a Rat Model for Chronic Hyperparathyroidism
Endocrinology, November 1, 2008; 149(11): 5735 - 5746.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
S. De Geronimo, E. Romagnoli, D. Diacinti, E. D'Erasmo, and S. Minisola
The risk of fractures in postmenopausal women with primary hyperparathyroidism
Eur. J. Endocrinol., September 1, 2006; 155(3): 415 - 420.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
L. H. VanderWalde, I.-L. A. Liu, T. X. O'Connell, and P. I. Haigh
The Effect of Parathyroidectomy on Bone Fracture Risk in Patients With Primary Hyperparathyroidism
Arch Surg, September 1, 2006; 141(9): 885 - 891.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Arabi, N. Khoury, L. Zahed, A. Birbari, and G. El-Hajj Fuleihan
Regression of Skeletal Manifestations of Hyperparathyroidism with Oral Vitamin D
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2480 - 2483.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
D. K. McDonald, L. Parman, and V. O. Speights Jr
Best Cases from the AFIP: Primary Hyperparathyroidism Due to Parathyroid Adenoma
RadioGraphics, May 1, 2005; 25(3): 829 - 834.
[Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
S. Cheng, F. Tylavsky, H. Kroger, M. Karkkainen, A. Lyytikainen, A. Koistinen, A. Mahonen, M. Alen, J. Halleen, K. Vaananen, et al.
Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls
Am. J. Clinical Nutrition, September 1, 2003; 78(3): 485 - 492.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
K. Siminoski
Asymptomatic hyperparathyroidism: Is the pendulum swinging back?
Can. Med. Assoc. J., July 1, 2000; 163(2): 173 - 175.
[Full Text] [PDF]